Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1993 Jun;142(6):1916–1926.

Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.

J Zhang 1, E H Herman 1, V J Ferrans 1
PMCID: PMC1886987  PMID: 8506959

Abstract

Histological and immunohistochemical studies using specific monoclonal antibodies were made to evaluate the severity of the chronic cardiomyopathy and the quantitative changes in interstitial dendritic cells (antigen-presenting cells), T helper lymphocytes, T cytotoxic/suppressor lymphocytes, and macrophages in the hearts of spontaneously hypertensive rats (SHRs) treated with doxorubicin at 1 mg/kg per week for 3, 6, 9 or 12 weeks. In addition, an assessment was made of the modifications of the responses of these cell populations by pretreatment of the SHR with ICRF-187, which protects against doxorubicin cardiotoxicity. The number of interstitial dendritic cells/mm2 of section of left ventricle was similar in saline-treated control SHRs (76 +/- 6) and in those treated with ICRF-187 alone (75 +/- 2) but increased markedly (319 +/- 33) in animals receiving a total cumulative dose of 12 mg/kg doxorubicin. Treatment with ICRF-187 prior to each administration of doxorubicin attenuated in a dose-dependent manner the increase in numbers of dendritic cells induced by doxorubicin (231 +/- 47, 174 +/- 11, and 100 +/- 16 cells/mm2) after treatment with 6.25, 12.5, and 25 mg of ICRF-187, respectively. Doxorubicin also induced increases in the numbers of T helper lymphocytes and macrophages but not of T cytotoxic/suppressor lymphocytes. These increases were also attenuated by pretreatment with ICRF-187. These data were interpreted as indicating that doxorubicin cardiotoxicity results in the release of substances that initiate immune reactions involving the antigen-presenting cells of the heart and that such reactions are attenuated by pretreatment with ICRF-187.

Full text

PDF

Images in this article

1919Figure 1
on p.1919
1919Figure 2
on p.1919
1921Figure 3
on p.1921
1921Figure 4
on p.1921
1921Figure 5
on p.1921
1921Figure 6
on p.1921
1923Figure 7
on p.1923

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdul Hamied T. A., Turk J. L. Enhancement of interleukin-2 release in rats by treatment with bleomycin and adriamycin in vivo. Cancer Immunol Immunother. 1987;25(3):245–249. doi: 10.1007/BF00199154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arinaga S., Akiyoshi T., Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res. 1986 Aug;46(8):4213–4216. [PubMed] [Google Scholar]
  3. Balsari A., Alzani R., Parrello D., Morelli D., Tagliabue E., Gianni L., Isetta A. M., Menard S., Colnaghi M. I., Ghione M. Monoclonal antibodies against doxorubicin. Int J Cancer. 1988 Nov 15;42(5):798–802. doi: 10.1002/ijc.2910420528. [DOI] [PubMed] [Google Scholar]
  4. Brideau R. J., Carter P. B., McMaster W. R., Mason D. W., Williams A. F. Two subsets of rat T lymphocytes defined with monoclonal antibodies. Eur J Immunol. 1980 Aug;10(8):609–615. doi: 10.1002/eji.1830100807. [DOI] [PubMed] [Google Scholar]
  5. Cohen S. A., Salazar D., Wicher J. Adriamycin-induced activation of NK activity may initially involve LAF production. Cancer Immunol Immunother. 1983;15(3):188–193. doi: 10.1007/BF00199163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cole S. P., Campigotto B. M., Johnson J. G., Elliott B. E. Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant. Cancer Immunol Immunother. 1991;33(4):274–277. doi: 10.1007/BF01744948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dijkstra C. D., Döpp E. A., Joling P., Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology. 1985 Mar;54(3):589–599. [PMC free article] [PubMed] [Google Scholar]
  8. Ehrke M. J., Maccubbin D., Ryoyama K., Cohen S. A., Mihich E. Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res. 1986 Jan;46(1):54–60. [PubMed] [Google Scholar]
  9. Ehrke M. J., Ryoyama K., Cohen S. A. Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res. 1984 Jun;44(6):2497–2504. [PubMed] [Google Scholar]
  10. Green J., Jotte R. Interactions between T helper cells and dendritic cells during the rat mixed lymphocyte reaction. J Exp Med. 1985 Nov 1;162(5):1546–1560. doi: 10.1084/jem.162.5.1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hart D. N., Fabre J. W. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J Exp Med. 1981 Aug 1;154(2):347–361. doi: 10.1084/jem.154.2.347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hasinoff B. B. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions. 1989 Mar;26(3-4):378–385. doi: 10.1007/BF01967305. [DOI] [PubMed] [Google Scholar]
  13. Haskill J. S. Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res. 1981 Oct;41(10):3852–3856. [PubMed] [Google Scholar]
  14. Herman E. H., Ferrans V. J. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest. 1983 Jul;49(1):69–77. [PubMed] [Google Scholar]
  15. Herman E. H., Ferrans V. J., Myers C. E., Van Vleet J. F. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 1985 Jan;45(1):276–281. [PubMed] [Google Scholar]
  16. Herman E. H., Ferrans V. J. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res. 1981 Sep;41(9 Pt 1):3436–3440. [PubMed] [Google Scholar]
  17. Herman E. H., Ferrans V. J., Young R. S., Hamlin R. L. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 1988 Dec 1;48(23):6918–6925. [PubMed] [Google Scholar]
  18. Herman E. H., el-Hage A., Ferrans V. J. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol. 1988 Jan;92(1):42–53. doi: 10.1016/0041-008x(88)90226-8. [DOI] [PubMed] [Google Scholar]
  19. Huber S. A. Doxorubicin-induced alterations in cultured myocardial cells stimulate cytolytic T lymphocyte responses. Am J Pathol. 1990 Aug;137(2):449–456. [PMC free article] [PubMed] [Google Scholar]
  20. Maccubbin D. L., Whitman J. A., Taniguchi N., Mace K. F., Ehrke M. J., Mihich E. Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. Int J Immunopharmacol. 1988;10(3):317–323. doi: 10.1016/0192-0561(88)90064-1. [DOI] [PubMed] [Google Scholar]
  21. McMaster W. R., Williams A. F. Identification of Ia glycoproteins in rat thymus and purification from rat spleen. Eur J Immunol. 1979 Jun;9(6):426–433. doi: 10.1002/eji.1830090603. [DOI] [PubMed] [Google Scholar]
  22. Myers C. E., Gianni L., Simone C. B., Klecker R., Greene R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry. 1982 Apr 13;21(8):1707–1712. doi: 10.1021/bi00537a001. [DOI] [PubMed] [Google Scholar]
  23. Nio Y., Imai S., Shiraishi T., Ohgaki K., Tobe T. Lymphocytes anticancer chemosensitivity testing in vitro--an approach to predict immunosuppressive effect of anticancer agents. J Clin Lab Immunol. 1989 Jul;29(3):141–145. [PubMed] [Google Scholar]
  24. Parham P., Barnstable C. J., Bodmer W. F. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol. 1979 Jul;123(1):342–349. [PubMed] [Google Scholar]
  25. Perkins W. E., Schroeder R. L., Carrano R. A., Imondi A. R. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. Br J Cancer. 1982 Oct;46(4):662–667. doi: 10.1038/bjc.1982.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Spencer S. C., Fabre J. W. Characterization of the tissue macrophage and the interstitial dendritic cell as distinct leukocytes normally resident in the connective tissue of rat heart. J Exp Med. 1990 Jun 1;171(6):1841–1851. doi: 10.1084/jem.171.6.1841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Speyer J. L., Green M. D., Kramer E., Rey M., Sanger J., Ward C., Dubin N., Ferrans V., Stecy P., Zeleniuch-Jacquotte A. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988 Sep 22;319(12):745–752. doi: 10.1056/NEJM198809223191203. [DOI] [PubMed] [Google Scholar]
  28. Speyer J. L., Green M. D., Zeleniuch-Jacquotte A., Wernz J. C., Rey M., Sanger J., Kramer E., Ferrans V., Hochster H., Meyers M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992 Jan;10(1):117–127. doi: 10.1200/JCO.1992.10.1.117. [DOI] [PubMed] [Google Scholar]
  29. Steeg P. S., Moore R. N., Johnson H. M., Oppenheim J. J. Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med. 1982 Dec 1;156(6):1780–1793. doi: 10.1084/jem.156.6.1780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Steiniger B., Klempnauer J., Wonigeit K. Phenotype and histological distribution of interstitial dendritic cells in the rat pancreas, liver, heart, and kidney. Transplantation. 1984 Aug;38(2):169–174. doi: 10.1097/00007890-198408000-00016. [DOI] [PubMed] [Google Scholar]
  31. Van Schie R. C., De Mulder P. H., Verstraten H. G., Van Rennes H., Wagener D. J. In vitro studies on the influence of doxorubicin in combination with recombinant interferon-gamma on human monocytes. Anticancer Res. 1991 May-Jun;11(3):1245–1252. [PubMed] [Google Scholar]
  32. White R. A., Mason D. W., Williams A. F., Galfre G., Milstein C. T-lymphocyte heterogeneity in the rat: separation of functional subpopulations using a monoclonal antibody. J Exp Med. 1978 Sep 1;148(3):664–673. doi: 10.1084/jem.148.3.664. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES